30 closest matches · ranked by relevance
Liver Transplant · Liver Transplantation
Primary: Proportion of Participants Successfully Withdrawn From Immunosuppression — 0.60 Proportion of participants
End Stage Renal Failure With Renal Transplant
Primary: Change in T Cell & B Cell Generation — 1.05; 0.93; 0.8; 1.12 Mean % of Treg cells in peripheral blood
Kidney Failure
Primary: Serum Creatinine Concentration — 112 umol/L
Influenza, Human · Transplantation Infection
Primary: Number of Patients With Local Site Reactions — 2; 2 Participants
Kidney Transplantation
Primary: The Rate of Allograft Rejection — 0; 0 participants
Medication Adherence · Liver Transplantation · Kidney Transplantation
Primary: Medication Adherence Via Medication Level Variability Index (MLVI) — 23; 24; 10; 8 Participants
Lung Transplant
Primary: Percentage of Patients Remaining on Envarsus XR at 1 Year — 40 Participants
Hepatitis C · Hepatitis C, Chronic · Nonimmune Nonviral Causes of Liver Failure
Primary: Number of Participants With Clinical Complications Usually Attributed to Immunosuppression — 12; 4 participants
Kidney Transplantation
Primary: Post-transplant Biopsy to Identify Rejection Episodes — 2; 3 Episode of rejection
Immunosuppression
Primary: Mean International Society for Heart and Lung Transplantation Biopsy Score Over the First 6 Months Post-transplantation — 0.7; 0.65 units on a scale
Liver Transplant Recipient · Living Donor (of the Respective Liver Transplant Recipient)
Primary: Number of Participants Who Experienced Grade 3 or Higher Adverse Events (AEs) Deemed Attributable to darTreg Infusion — 0 Participants
Heart Failure
Primary: Sustained Virologic Response After Treatment — 24 Participants
Kidney Transplant
Primary: Number of Subjects With Antibody-Mediated Rejection (AMR) in the First 3 Months After Living Donor Kidney Transplantation — 2 Participants
Hepatitis C · Liver Transplantation
Primary: Number of Participants Sustained Virological Response (SVR) Following Treatment of Hepatitis C Virus (HCV) Infection With Peg-IFN and Ribavirin in Liver Transplanted…
Kidney Transplantation
Primary: Tacrolimus Bioavailability (F) — 0.224; 0.681 ratio of oral to IV — p=0.006
Liver Failure
Primary: The Incidence of Acute Kidney Injury (AKI) as Assessed by Change in Serum Creatinine From Baseline to 30 Days Post-transplant — .01; .06 mg/dL
Kidney Transplant Recipients · Liver Transplant Recipients
Primary: The -Fold Change in Antibody Titer (Using the Roche Elecsys® Anti-SARS-CoV-2 S Assay) From Before Receiving the Study Dose of Vaccine to 30 Days After the Study Dose of…
Actinic Keratosis
Primary: Number of Participants With Adverse Events — 12; 11; 6; 3 Participants
End Stage Renal Disease · Hepatitis C
Primary: Viral Response at Week 12 — 10 Participants
Liver Carcinoma
Primary: Percentage of Participants Surviving at One and Four Years After Liver Transplant — 85; 77 percentage of participants
Highly-sensitized Kidney Transplant Recipients
Primary: The Number of Polyoma BK Viremia Patients — 5 Participants
End Stage Renal Disease (ESRD)
Primary: Number of Participants With Serious Infectious Complications Following Transplantation — 2 participants
Organ Transplantation
Primary: Number of Patients Successfully Withdrawn From Oral Immunosuppression — 12; 7 Participants
Kidney Transplantation · Kidney Disease
Primary: Number of Acute Rejections in All Enrolled Participants — 1 Rejection Events
Antibody-mediated Rejection · Hyperacute Rejection of Cardiac Transplant · Left Ventricular Dysfunction
Primary: Number of Participants of Pathologic Antibody-Mediated Rejection and Left Ventricular Dysfunction — 4 Participants
Kidney Transplant · Diabetes Mellitus, Type 2 · Diabetic Nephropathy
Primary: Freedom From Insulin Therapy Post Transplant — 3; 4 Participants
End Stage Renal Disease
Primary: The Percent of Sensitized Patients Treated With PRA Reduction Pharmacological Therapy, Including Cytogam, Who Become Cross-match Compatible With Potential Living Donor…
Transplant; Failure, Kidney
Primary: BPAR (Biopsy-proven Acute Rejection) Incidence During the First 12 Months Post-transplant — 1; 3 participants — p=0.32
End Stage Renal Disease · Hepatitis C
Primary: Viral Response as Assessed by Number of Participants With Undetectable Hepatitis C RNA — 10 Participants
Kidney Transplantation
Primary: Percentage of Clinically-suspected Biopsy-proven Acute Rejection (CSBPAR) at 6 Months — 7.7; 9.4 Percentage of participants